Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)
Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh financial data and merger status, offering traders new information to assess risk.
Market read
New earnings numbers and merger progress create a short‑term trading catalyst for SMTI.
What to watch
Strong gross margin stability (93%) and continued product demand may support longer‑term valuation.
Background
Sanara MedTech filed a Form 8‑K reporting its Q3 2026 results and progress on a pending merger with MiMedx.
Ticker impact
Q3 2026 earnings release showing 8% revenue growth but a net loss of $1.3M and pending merger with MiMedx.
likely pressure as the market prices in the loss and merger risk
Operating income fell sharply and legal expenses rose, while the pending merger adds execution risk.
Market effects
Medical‑technology sector sees modest revenue growth but heightened cost pressure.
US med‑tech stocks may face short‑term downside on earnings miss.
Limited; impact confined to niche surgical‑device niche.
Counterpoint
If the merger closes, synergies could unlock upside despite the short‑term loss.
Key entities
- companySanara MedTech Inc.
Medical‑technology firm reporting Q3 2026 results.
- companyMiMedx Group, Inc.
Potential acquirer in a pending merger.



